ASCVD Incretin Step-Therapy Criteria Pack
A policy guide for health plans to prioritize lower-cost diabetes drugs for patients with heart disease.
A ready-to-deploy utilization-management policy module for PBMs and health plans that uses the new noninferiority-without-superiority cardiovascular evidence to place the typically lower-priced dulaglutide first for members with type 2 diabetes and established heart disease, with defined exceptions for weight-priority patients.
Concept
A pre-written utilization-management module covering incretin therapy in members with type 2 diabetes and established atherosclerotic cardiovascular disease. Contents: prior-authorization criteria (dulaglutide 1.5 mg first-line when cardiovascular protection is the indication), explicit exception criteria (BMI/obesity-comorbidity thresholds, documented GI intolerance, glycemic failure), member and physician communication scripts, appeals-response templates citing the trial, and a dashboard tracking persistence and weight outcomes. The single wedge: a defensible, evidence-cited cost gate for the highest-spend drug class in this population.
Why now
SURPASS-CVOT showed tirzepatide is noninferior — but not superior — to dulaglutide for cardiovascular death, myocardial infarction, or stroke (12.2% vs 13.1% of patients; hazard ratio 0.92, 95.3% CI 0.83–1.01; superiority P=0.09 not met), while causing more GI events (42.5% vs 35.9%) and more discontinuation (13.2% vs 10.1%). For payers facing exploding incretin budgets, this is the first head-to-head evidence base for step therapy that prioritizes the cheaper, better-tolerated, cardiovascular-proven agent in ASCVD members while carving out weight-priority exceptions — and the AHA's 2026 statistics [5] quantify the cardiovascular-kidney-metabolic risk-factor burden driving that spend.
Written by GLM · 9 Oct 2026
AI assessment
A highly pragmatic, evidence-backed B2B tool that converts a specific clinical non-inferiority finding into immediate cost-savings for high-spend payers.
- Evidence strength 5/5
- The idea directly leverages the SURPASS-CVOT results (non-inferiority, higher GI events, and higher discontinuation for tirzepatide) to justify a specific clinical step-therapy sequence.
- Market pull 5/5
- PBMs and health plans have an urgent, high-priority need to control the exploding costs of incretin therapies without compromising cardiovascular outcomes.
- Novelty & moat 3/5
- While it shares the same evidence base as the 'ASCVD Incretin Switch Card,' it shifts the value proposition from clinical decision support to a financial/regulatory utilization-management tool.
- Feasibility 5/5
- The product is essentially a set of policy documents, scripts, and criteria, requiring no complex software development to create a minimum viable product.
- Wedge clarity 5/5
- The wedge is a single, sharp cost-gate for a specific patient population (T2D with ASCVD) based on a specific trial result.
- Simplicity / focus 5/5
- It avoids 'platform' creep by focusing on a single, ready-to-deploy policy module for a specific drug class.
Scored by Gemma 4 · 9 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Business analysis
The PESTEL analysis reveals a strong economic and technological alignment, as payers are desperate for cost-containment tools backed by head-to-head clinical data. However, the idea faces significant social and legal headwinds due to the high patient demand for weight-loss efficacy and potential physician pushback against restrictive step-therapy.
Political2
Economic2
Social2
Technological2
Environmental1
Legal2
The viability of utilization-management policies is heavily dependent on healthcare regulations, legal defensibility of step-therapy, and evolving clinical guidelines. · Generated 2026-10-09 by Gemma 4AI-generatedFull PESTEL Analysis →
Who benefits
- CVS Caremarkcompany
As one of the largest PBMs, it needs defensible, evidence-cited criteria to manage incretin spend; the non-superiority finding gives it a clinically grounded basis for step therapy in ASCVD members.
- Express Scripts (Evernorth)company
Its formulary teams face the same GLP-1 budget pressure and can deploy the criteria pack across commercial and government lines of business with the trial numbers pre-cited for appeals.
- National Association of Medicaid Directorsorganization
State Medicaid programs are among the most strained payers for incretin drugs; a ready-made, evidence-based criteria pack lets them implement step therapy without building clinical policy from scratch.
- Elevance Healthcompany
As a major national insurer, it can adopt the module to slow tirzepatide-first prescribing in its large diabetic-ASCVD membership while documenting exceptions for obesity-priority patients.
- Business Group on Healthorganization
Its large-employer members fund GLP-1 benefits directly; an evidence-cited step-therapy framework helps them cover cardiovascular protection affordably while reserving tirzepatide for members who need the weight benefit.
Research it builds on
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristicsStephen James Nicholls, Deepak L. Bhatt, John B. Buse et al. · 2023 · 243 citationsAll ideas from this paper →
- 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart AssociationLatha P Palaniappan, Norrina B. Allen, Zaid Almarzooq et al. · 2026 · 223 citationsAll ideas from this paper →
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesStephen James Nicholls, Imre J. Pavo, Deepak L. Bhatt et al. · 2025 · 188 citationsAll ideas from this paper →
- Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetesDarren K. McGuire, David D. D’Alessio, Stephen James Nicholls et al. · 2022 · 12 citationsAll ideas from this paper →